Stayble Therapeutics AB (STU:4K4) Institutional Ownership : 0.01% (As of May. 28, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Stayble Therapeutics AB Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Stayble Therapeutics AB's institutional ownership is 0.01%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Stayble Therapeutics AB's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Stayble Therapeutics AB's Float Percentage Of Total Shares Outstanding is 0.00%.

Stayble Therapeutics AB Institutional Ownership Historical Data

The historical data trend for Stayble Therapeutics AB's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stayble Therapeutics AB Institutional Ownership Chart

Stayble Therapeutics AB Historical Data

The historical data trend for Stayble Therapeutics AB can be seen below:

	2023-05-31	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-03-31
Institutional Ownership	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01

Stayble Therapeutics AB Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Stayble Therapeutics AB (STU:4K4) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stayble Therapeutics AB (STU:4K4) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

STABL:Sweden 4K4:Germany

Address

Medicinaregatan 8a, Gothenburg, SWE, SE-413 90

Website

http://www.staybletherapeutics.com

Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.

Stayble Therapeutics AB (STU:4K4) Headlines

No Headlines